iDEL Therapeutics has entered a multi-year research collaboration with Daiichi Sankyo to investigate a new approach to delivering combination cancer therapies directly into solid tumor cells. The agreement will focus on the preclinical evaluation of a multi-drug conjugate (MDC) developed using iDEL’s synthetic shuttle technology. Researchers from iDEL and Daiichi Sankyo’s Research Institute Munich will assess the candidate’s performance against an antibody-drug conjugate (ADC) carrying a comparable payload.
The collaboration will explore whether iDEL’s delivery platform can overcome limitations associated with cellular drug uptake and endosomal entrapment, which can prevent therapeutic compounds from reaching their intended intracellular targets. iDEL is developing its technology to transport therapeutic payloads directly into the cytosol, aiming to improve intracellular drug exposure and expand access to targets that have historically been difficult to address with conventional therapies.
Beyond the Daiichi Sankyo collaboration, iDEL plans to continue advancing its delivery platform with the aim of improving therapeutic windows and expanding treatment options for cancer patients.
Source: drug-dev.com · Image: Sugar chemistry room- central cancer research laboratory by Unknown photographer, Public domain, via Wikimedia Commons
Start your 7-day trial and see what the database can do →
